NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that it has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable the pharmaceutical and life science industries to advance discoveries and deliver groundbreaking treatments to patients.
Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.
“We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients,” remarked André-Michel Ballester, NAMSA CEO. “NAMSA and WuXi AppTec’s Medical Device Testing Operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating MedTech innovation and helping Sponsors deliver life-saving medical technology throughout the world,” concluded Ballester.
The MedTech industry faces more stringent regulatory and clinical evidence requirements, which can delay development, increase costs, and slow market entry. NAMSA’s strategic outsourcing and comprehensive in-house services help MedTech innovators mitigate risk, shorten time to market and enhance stakeholder value.
Both companies will work closely to ensure a smooth transition for employees and customers.
NAMSA is an ARCHIMED company; acquired by the healthcare-focused global private equity firm in 2020. The acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations is the 9th acquisition by NAMSA since becoming an ARCHIMED company.
